<span id="midArticle_start"/> (Reuters) - Ocular Therapeutix Inc says itslead eye drug failed to meet one of the main goals in a secondlate-stage study.
<span id="midArticle_0"/>The drug, OTX-DP, was effective in reducing pain in patientswho had cataract surgery, but failed to reduce the inflammationin the eyes, the company said.
<span id="midArticle_1"/>Both endpoints needed to be met for the trial to beconsidered successful, Ocular Therapeutix said.
<span id="midArticle_2"/>Trading in the company's stock was halted on the Nasdaq.
<span id="midArticle_3"/>Ocular Therapeutix said in March that the drug reduced painand inflammation in patients in a first late-stage trial. (Reporting by Rosmi Shaji in Bengaluru; Editing by SavioD'Souza)
<span id="midArticle_4"/>
<span id="midArticle_0"/>The drug, OTX-DP, was effective in reducing pain in patientswho had cataract surgery, but failed to reduce the inflammationin the eyes, the company said.
<span id="midArticle_1"/>Both endpoints needed to be met for the trial to beconsidered successful, Ocular Therapeutix said.
<span id="midArticle_2"/>Trading in the company's stock was halted on the Nasdaq.
<span id="midArticle_3"/>Ocular Therapeutix said in March that the drug reduced painand inflammation in patients in a first late-stage trial. (Reporting by Rosmi Shaji in Bengaluru; Editing by SavioD'Souza)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1adiIx7
No comments:
Post a Comment